Monitor for any future 8-K filings for material agreements or amendments to the plan — the expanded severance coverage increases potential cash liability in a restructuring scenario. No immediate catalyst.
Price Chart
Executive Summary
Vistagen Therapeutics adopted an amended and restated Executive Severance Plan on October 7, 2026, expanding severance benefits to include involuntary terminations without Cause outside of a Change in Control. The plan provides lump-sum cash payments equal to monthly base salary times a tiered severance period (4-12 months for officers) plus COBRA premium payments, and full equity acceleration upon a qualifying termination during a Change in Control period. This is a routine compensatory arrangement with no financial figures disclosed.
Key Facts
- Plan expanded to cover terminations without Cause outside a Change in Control (previously only within Change in Control Period)
- Severance tiers: CEO per individual agreement; Chief Officers 12 months; SVP 6 months; VP 4 months base pay and COBRA
- Equity acceleration only applies to CIC Qualifying Terminations (within 3 months before to 18 months after a Change in Control)
- Eligibility requires 12 months of full-time employment; all current executive officers are eligible
- Plan effective October 7, 2026, amends and restates the prior plan from August 11, 2026
Financial Impact
No dollar amounts disclosed; maximum potential liability depends on executive salaries and COBRA premiums at time of termination
Risk Factors
- Expanded severance obligations could increase cash burn if multiple executives are terminated without Cause
- Equity acceleration upon CIC Qualifying Termination could dilute existing shareholders if a Change in Control occurs
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-065559 |
| Document: vtgn-20261007.htm | 0001628280-26-065559 |
| Document: 0001628280-26-065559-index-headers.html | 0001628280-26-065559 |
| Document: 0001628280-26-065559-index.html | 0001628280-26-065559 |
| Document: 0001628280-26-065559.txt | 0001628280-26-065559 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $0.2300 $0.2000 | ▼ −13.04% | ▼ −11.55% | $0.1738 (−24.43%) |
Sep 25, 2026 4w ago | 8-K | $0.2700 $0.2800 | ▲ +3.70% | ▲ +3.93% | $0.1738 (−35.63%) |
Sep 24, 2026 4w ago | 8-K | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1738 (−41.08%) |
Sep 24, 2026 4w ago | Press Release | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1738 (−41.08%) |
Aug 14, 2026 10w ago | 8-K | $0.2676 $0.2440 | ▲ +8.82% | ▲ +7.45% | $0.1738 (+35.05%) |
Aug 14, 2026 10w ago | Press Release | $0.2676 $0.2440 | ▼ −8.82% | ▼ −7.45% | $0.1738 (−35.05%) |
Jul 31, 2026 12w ago | 8-K | $0.2410 $0.2876 | ▲ +19.34% | ▲ +15.82% | $0.1738 (−27.88%) |
Jun 30, 2026 16w ago | 8-K | $0.2260 $0.2458 | ▼ −8.76% | ▼ −8.16% | $0.1738 (+23.10%) |
Jun 17, 2026 18w ago | 8-K | $0.6702 $0.6166 | ▼ −8.00% | ▼ −6.33% | $0.1738 (−74.07%) |
Jun 15, 2026 19w ago | 8-K | $0.6900 $0.6323 | ▼ −8.36% | ▼ −6.13% | $0.1738 (−74.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers